Xeltis AG
http://www.xeltis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xeltis AG
Minute Insight: Xeltis’ Vascular Access Graft Stays Patent In First-In-Human Trial
Xeltis’ aXess graft demonstrated high patency rates and no infections after six months in the first-in-human trial.
Minute Insight: Xeltis Expects The US Trial Of 'Living' Vascular Graft To Start This Year
Xeltis hemodialysis access graft, made of its proprietary electrospun supramolecular polymer material, is advancing in clinical trials in Europe and will likely be ready for a US trial by the end of this year, according to the company.
European Investor LSP Raises $600M For Life Sciences Fund
LSP says its new fund for medical device and drug development companies will be the biggest fund dedicated to life sciences companies in Europe.
Market Intel: Martin Leon's TAVR Technology Tour Of The Future
Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice